Francis et al. effectively identified clonal events in GBM and revealed subclonal diversity of oncogenic EGFR and its implication in resistance to treatment for EGFR inhibitors, revealing the broad implications of clonal status in resistance to treatment [21]. This evidence concerns the gene EGFR and glioblastoma.